We quantitatively analysed hypermethylation at CpG islands in the 5' ends of 12 genes and one non-CpG island 5' region (MTHFR) in 31 Wilms tumors. We also determined their global genomic 5-methylcytosine content. Compared with various normal postnatal tissues, *40 -90% of these pediatric kidney cancers were hypermethylated in four of the genes, MCJ, RASSF1A, TNFRSF12 and CALCA as determined by a quantitative bisulfite-based assay (MethyLight). Interestingly, the non-CpG island 5' region of MTHFR was less methylated in most tumors relative to the normal tissues. By chromatographic analysis of DNA digested to deoxynucleosides, about 60% of the Wilms tumors were found to be deficient in their overall levels of DNA methylation. We also analysed expression of the three known functional DNA methyltransferase genes. No relationship was observed between global genomic 5-methylcytosine levels and relative amounts of RNA for DNA methyltransferases DNMT1, DNMT3A, and DNMT3B. Importantly, no association was seen between CpG island hypermethylation and global DNA hypomethylation in these cancers. Therefore, the overall genomic hypomethylation frequently observed in cancers is probably not just a response or a prelude to hypermethylation elsewhere in the genome. This suggests that the DNA hypomethylation contributes independently to oncogenesis or tumor progression.
Introduction
Numerous recent studies have described cancer-associated hypermethylation in CpG-rich 5' gene regions (Baylin and Herman, 2000; Issa, 2000) . However, net decreases in DNA methylation in cancer often exceed the localized increases in DNA methylation associated with carcinogenesis (Ehrlich, 2000; Gama-Sosa et al., 1983) . The importance of cancer-linked hypermethylation of transcription control regions is clear because of the consequent transcriptional silencing, especially for tumor suppressor genes (Baylin and Herman, 2000; Issa, 2000) , but the biological significance of DNA hypomethylation in cancers is less certain.
Global DNA hypomethylation may be as frequent in cancer as CpG island hypermethylation. It has been found in various cancers, especially metastases, in a study in which cancers were compared to a wide range of normal tissues (Gama-Sosa et al., 1983) . Global DNA hypomethylation has also been seen in comparisons of diverse types of cancers and adjacent, apparently normal tissues (reviewed in Ehrlich, 2002) . For ovarian epithelial tumors, a low overall genomic DNA methylation level (relative to that of various normal tissues) has been shown to be significantly associated with the degree of malignancy (benign cystadenomas, low malignant potential tumors, or adenocarcinomas; Cheng et al., 1997; Qu et al., 1999a) .
In this study on epigenetic changes in Wilms tumors, we present the first comparison of cancer-linked global genomic hypomethylation and hypermethylation at multiple CpG islands in the same tumors. We found that CpG island hypermethylation was neither positively nor negatively associated with global DNA hypomethylation. Also, we showed that global DNA methylation was not associated with the relative levels of RNA from the DNA methyltransferase genes DNMT1, DNMT3A and DNMT3B.
Results

Frequent global DNA hypomethylation in Wilms tumors
As in our previous studies of differences in human DNA methylation levels among normal human tissues and between normal tissues and cancers (not including Wilms tumors), the m 5 C content was determined on DNA digested to deoxynucleosides (Ehrlich et al., 1982; Gama-Sosa et al., 1983) . The choice of normal tissue for m 5 C content comparisons is complicated by the fact that Wilms tumors are derived from the embryonic metanephric blastema, which is usually eliminated during embryonic development and, if not, in infancy. Furthermore, histologically normal kidney tissue of Wilms tumor patients may contain foci of abnormal cells. Because normal kidney is not an appropriate control for Wilms tumors, we used a panel of adult normal human tissues for comparison. We set the criterion for global hypomethylation of Wilms tumor DNA as lower levels of genomic m 5 C than seen in the normal postnatal somatic tissue with the lowest m 5 C content in its DNA (heart DNA, Table 1 ). Out of 31 tumors obtained before treatment, 19 displayed global DNA hypomethylation by this criterion. There was no significant association of global DNA hypomethylation with tumor stage.
CpG island hypermethylation in Wilms tumors
We used MethyLight, a bisulfite modification-dependent, fluorescence-based real-time PCR assay (Eads et al., 2000) , to analyse CpG island methylation in Wilms tumors. Controls of unmethylated DNA and in vitro methylated DNA were included in each analysis. Methylation is detected when template sequences corresponding to both of the primers and the probe for a given CpG island are methylated at multiple CpGs. From 5 (e.g. ICAM1) to 11 (e.g. CXADR) CpGs were analysed per reaction. To adjust for differences in genomic DNA integrity and quantity, each methylation measurement was normalized against PCR results from the same sample at a DNA sequence containing no CpGs. This ratio was then further normalized to a common reference sample, in vitro methylated sperm DNA. The resulting value is expressed as a percentage of this methylated reference (PMR, see Materials and methods). PMR values can exceed 100, if the reference DNA sample was not fully methylated in vitro. This does not affect comparisons among various test samples, which are all made relative to the same reference sample. This method has been extensively validated as to its specificity, sensitivity, reproducibility, and quantitative nature by comparison to the quantitative combined bisulfite restriction analysis and bisulfite-based genomic sequencing (Eads et al., 2000) .
We initially screened DNA from 10 Wilms tumor samples for hypermethylation at 30 different CpG-rich gene regions. Seventeen of these loci showed little or no methylation and were not considered for further analysis. These included CDKN2A, APC, ARF, Tables 2 -4 ). We also analysed the 5' CpG islands of CALCA, a cancer hypermethylation marker gene (Issa, 2000) ; PTGS2 (cyclooxygenase 2), a candidate proto-oncogene (Toyota et al., 2000) ; ICAM1 (intracellular adhesion molecule 1), a gene that is upregulated in nasopharyngeal carcinoma (Busson et al., 1992) ; and CXADR (Homo sapiens coxsackie virus and adenovirus receptor). The only 5' region that did not satisfy the formal criteria for CpG islands (Gardiner-Garden and Frommer, 1987) was that of MTHFR (methylene tetrahydrofolate reductase) (Eads et al., 2001 ). Interestingly, this 5' region was the most consistently methylated at high levels among the normal tissues analysed ( Table 2 ). Most of the 12 CpG islands exhibited little or no CpG methylation in the normal tissues examined (Table 2 ). However, MGMT and TNFRSF12 displayed appreciable methylation in many of the normal tissue samples and RASSF1A showed tissue-specific differences in methylation.
Significant hypermethylation of RASSF1A, TNFRSF12, MCJ and CALCA CpG islands (P50.0005, P50.01, P50.0001 and P50.09, respectively) was seen in Wilms tumors (Table 3 , bold typeface PMR values) relative to various normal tissues, including morphologically normal tumor-adjacent tissue (Table 2 ). About 75, 65, 90 and 40% of the tumors were hypermethylated in the 5' CpG islands of these genes, respectively. The tumor samples in Tables  1 and 3 were from previously untreated patients and included a tumor obtained before chemotherapy from one kidney of a patient (WT10). We also analysed a tumor obtained from the other kidney of this patient after chemotherapy (WT25). These bilateral tumors differed in CpG island hypermethylation. WT10 displayed hypermethylation in both RASSF1A and MCJ, but WT25 exhibited hypermethylation in RASSF1A and TNFRSF12 instead of MCJ (Table 3 and data not shown). Also, WT10 had much global DNA hypomethylation while WT25 had DNA methylation levels within the normal range (Table 1 and data not shown). Similarly, WT10 had much more satellite DNA hypomethylation than WT25 .
We had sufficient amounts of sample to analyse methylation of the RASSF1A, TNFRSF12, and MCJ 5' CpG islands in two Wilms tumor patients for whom matched sets of nephrogenic rest, tumor, and normal post-natal kidney samples were available. Nephrogenic rests are precursor lesions associated with Wilms tumors and, like Wilms tumors, contain blastemal cells (undifferentiated mesenchymal cells). They are often found in kidneys of Wilms tumor patients. Both nephrogenic rest samples showed negligible methylation of the RASSF1A and MCJ CpG islands unlike the corresponding Wilms tumors, which were extensively hypermethylated in these regions (data not shown). Furthermore, in contrast to Wilms tumors, we observed negligible levels of RASSF1A, TNFRSF12 and MCJ CpG island methylation in a 22-week fetal kidney DNA. Therefore, hypermethylation of RASS-F1A, TNFRSF12 and MCJ CpG islands is tumorspecific and not merely reflective of an oncofetal expansion of blastemal cells, embryonic kidney precursor cells.
There are CpG-rich regions that are appreciably methylated in a variety of normal somatic tissues (Zhang et al., 1987; Strichman-Almashanu et al., 2002) . The MethyLight assay revealed statistically significant hypomethylation of one such region, the 5' end of Table 2 The extent of methylation of 13 5' CpG-rich sequences in normal tissues Tables 2 and 3 ). In contrast to the other examined 5' CpG-rich regions, which showed either increased methylation or no change in tumors compared to control tissues, MTHFR's CpG-rich region does not fulfil the definition of a CpG island, as mentioned above. It is not as highly enriched in CpG's (observed/expected CpG, 0.56; 56.5% G+C) and encompasses only about 200 bp.
The PMR values for the extent of methylation are obtained from a ratio of measurements of the gene of interest and of a CpG-free DNA locus elsewhere in the genome. Cytogenetic abnormalities involving these regions would affect this ratio, independently of methylation status. We had analysed the tumor samples cytogenetically . Therefore, we checked whether the PMR values for the five genes with the most significant tumor-linked methylation differences (MCJ, RASSF1A, MTHFR, TNFRSF12 and CALCA) required adjustment due to chromosome arm imbalances in any of the tumors. These genes are located at 13q14.1, 3p21.3, 1p36.1, 1p36.2-p36.3, and 11p15.2-p15.1, respectively. The only test genes for which this correction was necessary were MCJ and RASSF1A. With respect to RASSF1A on 3p21, two of the tumors (WT5 and WT6) with an extra copy of chromosome 3 showed high PMR values for the RASSF1A CpG island indicative of extensive methylation in this region. Similarly, the seven tumors that exhibited gains of chromosome 13 (#s 1, 11, 14A, 15, 16, 27, and 33) showed higher PMRs for the MCJ CpG island methylation at 13q14 (Table 3) than the normal somatic tissues (Table 2 ). For MethyLight, the CpG-free standard sequence was in ACTB at 7p15-p12. From the cytogenetic data, its copy number was deduced to be abnormal for four tumors, namely, WT15 and WT30 (copy number 3), WT7 (copy number 1), and WT1 (average copy number 3.2). The PMR values reported in Table 3 have been corrected for all of these alterations in copy number.
We also compared DNA hypermethylation and hypomethylation. We found no significant associations between the methylation status of any of the 13 studied CpG-rich regions and global methylation levels (Table (Figure 1 and data not shown). The examined tumor DNAs included samples that had very low global DNA methylation levels (3.08 -3.20% C residues methylated) as well as those in the range of normal tissues (3.40 -3.90% C residues methylated). We did not observe an association between global DNA hypomethylation and the amounts of RNA for any of the DNMT genes (P=0.51, 0.32, and 0.44 for genomic m 5 C levels and DNMT1, DNMT3A, and DNMT3B expression, respectively). Furthermore, we did not observe a significant association between Figure 1 Relative expression levels of DNMT1, DNMT3A and DNMT3B in Wilms tumors. Steady-state mRNA levels of DNMT genes were determined from total RNA preparations of 15 Wilms tumors (WT1, 2, 5, 6, 9, 11, 14A, 20, 21, 23, 27, 28, 29, 30, 33) using real-time fluorescence-based RT -PCR (TaqMan). The expression levels were calculated as the ratio between the DNMT gene measurement and each of the reference gene measurements (average of H4F2 and PCNA), to correct for variations in the amounts of RNA. H4F2 and PCNA are cell-cycle regulated like the DNMT genes. The reference gene-normalized DNMT expression levels of Wilms tumors are shown relative to the average expression level for all tumors. For every examined tumor, these relative values for each DNMT measurement were plotted against the global methylation levels (% C methylated) and PTGS2, and primer and probe sequences for MethyLight analysis of these regions were previously described (Eads et al.,
2001)
Wilms tumor DNA hypomethylation and hypermethylation M Ehrlich et al methylation levels at any of the 13 gene regions and expression of any of the three DNMT genes (39 individual comparisons).
Discussion
We compared DNA hypomethylation and hypermethylation in Wilms tumors, a type of cancer whose composition of 580% cancer cells is well suited for this type of study. Frequent hypermethylation of some CpG islands was observed (Table 3) , as is the case for most kinds of cancer. Previously, regional cancerlinked alterations in methylation in Wilms tumors have been reported for gene regions associated with imprinting, the WT1 gene, and the CpG island in the 5' region of CDKN2A (p16) (Arcellana-Panlilio et al., 2000; Malik et al., 2000; Mares et al., 2001; Tycko, 2000) and recently for RASSF1A (Harada et al., 2002) . In the present study, comparing Wilms tumors and normal tissues, there was highly significant hypermethylation of CpG islands near the 5' ends of MCJ, RASSF1A, and TNFRSF12 as well as significant hypermethylation of a tumor marker gene CALCA (Tables 2 and 3 ). Of particular interest is the MCJ CpG island, which was hypermethylated in about 90% of the Wilms tumors, with very low levels of CpG island methylation in normal tissues. This gene encodes a protein related to the E. coli heat shock protein DNAJ, and may play a role in enhanced sensitivity to cancer chemotherapeutic drugs. The only previous report of aberrant methylation of this newly identified gene was about hypermethylation of its 5' CpG island in ovarian carcinomas, in which LOH of one allele and reduced or lost expression of MCJ was often seen (Shridhar et al., 2001) . The second most frequently hypermethylated CpG island observed in the Wilms tumors was in the 5' region of RASSF1A (Tables 3 and  4 ). This gene is implicated as a suppressor of kidney tumor formation (Dreijerink et al., 2001) and is frequently hypermethylated in clear cell renal carcinomas as well as various other cancers (Burbee et al., 2001) . In this study we compensated for increased copy numbers of genes due to numerical aberrations or partial chromosome duplications in the tumors. Gains in chromosomes containing MCJ or RASSF1A were usually accompanied by hypermethylation of the 5' CpG islands of these genes. This suggests that promoter region hypermethylation sometimes mitigates the cancer-antagonistic effects of extra copies of tumorsuppressor genes in aneuploid tumors. We also report for the first time that most Wilms tumors display global genomic hypomethylation (Table  1 ), as has been described for some other types of cancers (Feinberg and Vogelstein, 1983; Gama-Sosa et al., 1983; Ehrlich, 2000) . Given the tissue-specific differences in overall m 5 C levels in human DNA (Ehrlich et al., 1982) (Table 1 ) and the origin of Wilms tumors from embryonic tissue, we compared tumors to a wide variety of postnatal somatic tissues. We define tumor DNA hypomethylation as less methylation in the genome than in the least methylated normal postnatal somatic tissue in the controls. Therefore, we may underestimate hypomethylation in tumors that have only a small degree of DNA hypomethylation. Nonetheless, about 60% of the tumors were found to be hypomethylated.
Previously, Wilms tumor-specific gene-region hypomethylation was reported only for several imprinted regions (Malik et al., 2000; Tycko, 2000) . Comparison in the MethyLight assay of various normal tissue DNAs with Wilms tumor DNA samples revealed a region of significant tumor-specific hypomethylation, namely, the CpG-rich 5' end of MTHFR (P50.001; Table 3 ). MTHFR is on a subband of lp36 neighboring that of TNFRSF12. It is widely expressed, but its RNA is present at only low levels (Gaughan et al., 2000) . As described above, its partially CpG-rich 5' region does not fulfil the typical criteria of a CpG island and this may be why it escaped the hypermethylation seen for some of the other examined 5' gene regions.
For several reasons, it does not appear that the observed tumor-associated alterations in DNA methylation can be ascribed to the young age of most of the patients and age-related changes in DNA methylation. No consistent differences were apparent in the methylation status of any of the studied DNA sequences between control tissues from an individual less than 20 years and one more than 60 years (Table  2) . These are age cut-offs for which age-related DNA hypermethylation differences were previously established (Issa, 2000) . Age-dependent changes in DNA methylation have been observed between young and old individuals but not between individuals much younger than 20 vs those aged 20 -30 years (Ahuja et al., 1998; Issa et al., 1996) . These changes usually pertain to CpG island hypermethylation (Issa, 2000) , although not always (Yung et al., 2001) . One of the CpG islands for which increasing age was found to be associated with more methylation is that of ESR1 (Ahuja et al., 1998) . Ahuja et al. (1998) demonstrated an age-dependency for increased methylation of this 5' island both in normal liver and colon but, nonetheless, they observed significant tissue-specific differences. In our study of five types of normal tissue that had not been analysed for age-dependency of ESR1 methylation by Ahuja et al. (1998) , we found no detectable changes in methylation with age (Table 2) . To further address the question of whether age-related differences in DNA methylation contributed to our results, we compared Wilms tumor kidney tissue from two patients with adjacent kidney samples that contained no signs of nephroblastomatosis. In the comparison of these age-matched tissues, we again observed cancer-associated CpG island hypermethylation (Tables 2 and 3) .
Furthermore, these alterations in methylation in Wilms tumors are not just due to the embryonic nature of the tissue from which these pediatric cancers arise. First, in contrast to Wilms tumors, we observed negligible levels of RASSF1A and MCJ CpG island methylation and no satellite DNA hypomethylation (data not shown) in DNA from nephrogenic rests (Wilms tumor precursors) or 22-week fetal kidney. Furthermore, the global DNA demethylation, including satellite DNA demethylation that occurs from the one-cell through the morula stage is reversed by genome-wide remethylation just before or during implantation throughout the early embryoblast (Chapman et al., 1984; Oswald et al., 2000; Razin and Kafri, 1994; Santos et al., 2002) . Although there are methylation changes later in embryogenesis, they are much less wide-spread (Razin and Kafri, 1994) . Nonetheless, as for many types of cancer, there is the possibility that during oncogenesis there was selection for rare cells in the untransformed precursor tissue that had pre-existing hypomethylation or hypermethylation in the studied DNA sequences.
The quantitative nature of the MethyLight assay for local methylation changes and the inclusion of diverse postnatal somatic tissues of normal origin make our results on regional DNA methylation especially informative. For example, the hypermethylation of TNFRSF12 (DR3 or TRAMP) in more than half of the cancers (Table 3) could not have been detected without this quantitation, given the considerable levels of methylation of this sequence in normal tissues (Table  2) . TNFRSF12 is a member of the TNFR superfamily implicated in the apoptotic response to cellular insults (Wang et al., 2001) . Although cancer-associated changes in methylation or mutagenesis of TNFRSF12 have not been reported, evidence for cancer-linked deletion of TNFRSF12 on 1p36 has been found (Grenet et al., 1998) .
By the use of a quantitative DNA hypermethylation assay, we avoided potential false positive results from over-amplification of extremely low amounts of methylated DNA sequences. This might explain the discrepancy between our finding of negligible levels of methylation of the 5' CpG island of CDKN2A and the report by Arcellana-Panlilio et al. (2000) of methylation of this region in seven out of seven Wilms tumors exhibiting decreased CDKN2A expression. They used a non-quantitative methylation-specific PCR involving 45 cycles of amplification. In our quantitative assay, we found extremely low amounts of methylation in this region (PMR 0.003 -0.04; data not shown) for eight out of nine assayed tumor DNAs. Given the exponential nature of PCR amplification, these tumors might have appeared as positives in their assay.
Importantly, we found no association between the extent of methylation of any of the 13 CpG-rich regions in the 31 Wilms tumors analysed and their global DNA methylation levels. A negative association between CpG island methylation and global DNA hypomethylation would have been predicted if tumors with much CpG island hypermethylation were less likely to also display DNA hypomethylation. A positive association might have been seen if CpG island hypermethylation preceded and provoked global genomic hypomethylation or vice versa. CpG island hypermethylation and global hypomethylation have been reported to co-exist in cancers (Narayan et al., 1998; Ribieras et al., 1994; Ushijima et al., 1997) , but the association between the two has not been previously investigated for any tumor type. Our study indicates that these two cancer-associated mechanisms can occur independently of each other. This suggests that tumor-associated DNA hypomethylation contributes to carcinogenesis or tumor progression separately from aberrant DNA hypermethylation and its attendant silencing of tumor suppressor genes. The role of DNA hypomethylation in cancer may involve increasing karyotypic instability (Mitelman, http:// cgap.nci.nih.gov/Chromosomes/Mitelman, accessed 2001; Qu et al., 1999b; Tuck-Muller et al., 2000; Wong et al., 2001) and also altering gene expression (reviewed in Ehrlich, 2002) .
Materials and methods
Tissue samples and DNA isolation
Wilms tumor samples (Table 3) were obtained during nephrectomy of untreated patients except for WT14A, which was a biopsy sample. Informed consent was obtained from the patients or unlinked samples were used, with IRB approval in all instances. This set of tumors is different from the Wilms tumors described in our previous study (Qu et al., 1999b) . The control tissues were autopsy samples from trauma victims. DNA was purified from quick-frozen samples by standard methods (Ehrlich et al., 1982) . To quantitate the relative amounts of DNMT1, DNMT3A, and DNMT3B RNA in the different tumor samples, real-time RT -PCR was used on total RNA isolated and analysed as previously (Eads et al., 1999) with the exception that the following primers and probes were used for the H4F2 RT -PCR analyses: forward primer, 5'-TTCGGGACGCAGT-CACCTA-3'; reverse primer, 5'-AGCGCGTACACCACAT-CCAT-3'; and probe, 6FAM5'-CACGCCAAGCGCAAGA-CCGTC-3' TAMRA.
Quantitative analysis of methylation levels in CpG-rich regions of the genome The bisulfite modification-based MethyLight assay was used to quantitate methylation at CpG-rich regions (Table 4 ) (Eads et al., 2000 (Eads et al., , 2001 . The extent of methylation was determined by amplification of bisulfite-treated genomic DNA with primers and a probe specific for the bisulfiteconverted, fully methylated sequence for each gene (Table 4) . To control for the amount of input DNA, this value was normalized to the extent of amplification of an ACTB DNA sequence lacking CpG dinucleotides (Eads et al., 2001) . The percentage of fully methylated molecules at a specific CpGrich gene region was calculated by dividing the MethyLight signal for the given gene in the sample by that for ACTB in the sample DNA and then dividing that ratio by the analogous GENE:ACTB ratio for in vitro methylated sperm DNA and multiplying by 100. The value obtained is designated as the percentage of methylated reference (PMR) (Eads et al., 2001 ).
Statistical analysis
Samples of normal tissues (Table 1) were used for 10 independent control observations from the oldest and youngest autopsy samples available. The non-parametric Wilcoxon rank sum test was used to examine possible differences in hypermethylation of tumor and normal DNAs and to test whether global DNA hypomethylation is associated with regional hypermethylation in tumors (Hollander and Wolfe, 1973) . To test for a possible association between satellite DNA hypomethylation and regional hypermethylation, the Kruskal Wallis test was used with the satellite DNA hypomethylation scored as 7,+, or ++ . The test of Spearman correlation coefficient=0 was used to look for possible associations between tumor stage and individual PMR values or global DNA hypomethylation, and for possible associations between global hypomethylation and DNMT1, DNMT3A, and DNMT3B RNA levels (Hollander and Wolfe, 1973) .
